{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:21:42Z","timestamp":1791177702616,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ejca.2009.02.018","type":"journal-article","created":{"date-parts":[[2009,3,20]],"date-time":"2009-03-20T05:55:13Z","timestamp":1237528513000},"page":"1788-1797","source":"Crossref","is-referenced-by-count":50,"title":["Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study"],"prefix":"10.1016","volume":"45","author":[{"given":"Jean-Claude","family":"Barbare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lombard-Bohas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Faroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Raoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Cattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Zarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cazorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Gargot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Thevenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bedenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2009.02.018_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2009.02.018_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1089-3261(05)70107-0","article-title":"Hepatocellular cancer. A century of progress","volume":"4","author":"Kew","year":"2000","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ejca.2009.02.018_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1007117","article-title":"Epidemiology of primary liver cancer","volume":"19","author":"Bosch","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejca.2009.02.018_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-139-10-200311180-00009","article-title":"The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update","volume":"139","author":"El-Serag","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2009.02.018_bib5","first-page":"3","article-title":"Cancer incidence and mortality in France over the period 1978\u20132000","volume":"51","author":"Remontet","year":"2003","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.ejca.2009.02.018_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2008.01.022","article-title":"Novel advancements in the management of hepatocellular carcinoma in 2008","volume":"48","author":"Llovet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2009.02.018_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2009.02.018_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2009.02.018_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2168.2001.01644.x","article-title":"Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours","volume":"88","author":"Slooter","year":"2001","journal-title":"Brit J Surg"},{"key":"10.1016\/j.ejca.2009.02.018_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2009.02.018_bib11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/gut.45.5.766","article-title":"Regulatory peptide receptors in human hepatocellular carcinomas","volume":"45","author":"Reubi","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2009.02.018_bib12","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.3748\/wjg.v13.i23.3164","article-title":"The role of sandostatin LAR in treating patients with advanced hepatocellular cancer","volume":"13","author":"Dimitroulopoulos","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2009.02.018_bib13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gut.42.3.442","article-title":"Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study","volume":"42","author":"Kouroumalis","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2009.02.018_bib14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/he.2000.5628","article-title":"Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma","volume":"31","author":"The Cancer of the Liver Italian Program (CLIP) Investigators","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2009.02.018_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2009.02.018_bib16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/jhep.2002.35071","article-title":"A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma","volume":"36","author":"Yuen","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2009.02.018_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hep.21468","article-title":"Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study","volume":"45","author":"Becker","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2009.02.018_bib18","first-page":"1245","article-title":"The role of sandostatin LAR in treating patients with advanced hepatocellular cancer","volume":"49","author":"Dimitroulopoulos","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ejca.2009.02.018_bib19","first-page":"903","article-title":"Treatment of hepatocellular carcinoma with long acting somatostatin analogues","volume":"9","author":"Samonakis","year":"2002","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2009.02.018_bib20","first-page":"A145","article-title":"Search of somatostatin\u2019s receptors in hepatocellular carcinoma by the 111IN-pentetreotide scintigraphy in palliative situation: a French multicentric retrospective study","volume":"55","author":"Nguyen-Khac","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2009.02.018_bib21","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2009.02.018_bib22","doi-asserted-by":"crossref","unstructured":"Del Poggio P, Mattiello M, Gilardoni L, et al. The mysterious case of spontaneous disappearance of hepatocellular carcinoma. Dig Liver Dis [in press]. doi:10.1016\/j.dld.2008.02.001.","DOI":"10.1016\/j.dld.2008.02.001"},{"key":"10.1016\/j.ejca.2009.02.018_bib23","doi-asserted-by":"crossref","unstructured":"Del Prete S, Montella L, Addeo R, et al. Sorafenib plus long-acting octreotide in advanced hepatocellular carcinoma. Preliminary results of a multicenter ongoing study. Clin Oncol 2008;26(May 20 suppl; abstr 15624).","DOI":"10.1200\/jco.2008.26.15_suppl.15624"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T20:26:21Z","timestamp":1558211181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0959804909001245"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.02.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}